SCHEMBL7426726

SCHEMBL7426726

Cn1c(Cl)c(-c2ccccc2)nc(-c2ccccc2)c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.58
KDM4E B2RXH2 4/20 0.58
GAA P10253 3/20 0.58
HPGD P15428 2/20 0.58
CYP1A2 P05177 12/20 0.54
CYP3A4 P08684 4/20 0.54
TSHR P16473 2/20 0.54
CLK4 Q9HAZ1 1/20 0.54
GLA P06280 4/20 0.50
MAPT P10636 1/20 0.47
HSD17B10 Q99714 9/20 0.47
CASP7 P55210 7/20 0.47
CASP1 P29466 6/20 0.47
CYP2C9 P11712 5/20 0.47
HIF1A Q16665 4/20 0.47
CYP2C19 P33261 3/20 0.47
TP53 P04637 2/20 0.47
MAPK1 P28482 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
USP2 O75604 6/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15135212 0.79 ALDH1A1 (0.58) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL2220221 0.76 NPC1 (0.42) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL14006981 0.74 ALDH1A1 (0.66) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL14006985 0.74 ALDH1A1 (1.00) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL7415940 0.73 ALDH1A1 (0.56) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL28736705 0.73 ALDH1A1 (0.68) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL7694822 0.72 CYP1A2 (0.68) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL7698689 0.71 ALDH1A1 (0.61) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL15106581 0.70 ALDH1A1 (0.56) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL29935990 0.69 KDM4E (0.47) ALDH1A1KDM4EGAAHPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6352994-B2 NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS MERCK SHARP & DOHME LIMITED (GB) 2002-03-05 US disclosed
US-20010018438-A1 Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands MERCK SHARP & DOHME LIMITED 2001-08-30 US disclosed
US-6200982-B1 USEFUL IN THERAPY OF DELETERIOUS MENTAL STATES MERCK & DOHME LIMITED (GB) 2001-03-13 US disclosed
EP-0994873-A1 SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABA A?ALPHA 2/3 LIGANDS MERCK SHARP & DOHME LTD. (GB) 2000-04-26 EP disclosed
WO-1998055480-A1 SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABAAALPHA 2/3 LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1998-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018438-A1 Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands GABRB2, GABRB3, GABRB1 ALDH1A1 484/4885KDM4E 4019/4885GAA 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.